Treating the Resistant Patent Ductus Arteriosus (PDA)

Key facts

Sponsor

Shaare Zedek Medical Center

Principal Investigator

Cathy Hammerman, MD

Shaare Zedek Medical Center

Intervention

Indomethacin(drug)

Enrollment

68 enrolled

Eligibility

All sexes

Timeline

2008

Study locations (1)

• Neonatal Intensive Care Unit - Shaare Zedek Medical Center, Jerusalem, Israel

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Arterial duct anomaly

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT06950164
  Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• RECRUITINGNCT06658496
  PDA for Kidneys Study
  University of Wisconsin, Madison
• RECRUITINGNCT06646250
  NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot
  St. Olavs Hospital
• RECRUITINGPHASE2NCT07143201
  Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
  Hamilton Health Sciences Corporation
• RECRUITINGNCT05264753
  Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
  Occlutech International AB
• ACTIVE NOT RECRUITINGNCT04371081
  Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance
  Abbott Medical Devices
• ENROLLING BY INVITATIONNANCT04667455
  Improving Care for Children With Congenital Heart Disease.
  Lund University Hospital
• ACTIVE NOT RECRUITINGNCT03782610
  Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
  Nationwide Children's Hospital

See all trials for Arterial duct anomaly →